Immunic (IMUX) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immunic (IMUX) has outperformed Spruce Biosciences (SPRB) over the past year, gaining 1.9% versus a loss of 63.8%. Over five years, IMUX leads with a -91.9% price change compared with -99.8% for SPRB. Immunic is the larger company by market cap ($111.0 million vs $109.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | SPRB |
|---|---|---|
| Share price | $6.99 | $38.00 |
| Market cap | $111.01M | $109.21M |
| 1-day change | -5.41% | -6.15% |
| YTD return | +30.90% | -56.38% |
| 1-year return | +1.90% | -63.81% |
| 5-year return | -91.88% | -99.75% |
| Forward P/E | — | 11.79 |
| EPS (TTM) | $-3.53 | $-33.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-97.17M | $-38.97M |
| 52-week high | $17.43 | $111.00 |
| 52-week low | $5.06 | $38.00 |
| Distance from 52-week high | -59.90% | -65.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +508.73% | +288.00% |
| Average volume | 343.44K | 89.33K |
| Shares outstanding | 15.88M | 2.87M |
| Employees | 100 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed SPRB by 65.7 percentage points over the past year.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
IMUX vs SPRB FAQ
Which is bigger, Immunic or Spruce Biosciences?
Immunic (IMUX) is larger, with a market capitalization of $111.01M compared with $109.21M for Spruce Biosciences (SPRB).
Which stock has performed better over the past year, IMUX or SPRB?
IMUX returned +1.90% over the past 12 months, compared with -63.81% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.